{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:00:34Z","timestamp":1780088434378,"version":"3.54.0"},"reference-count":7,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,6]]},"abstract":"\n Introduction<\/jats:title>\n Non-Hodgkin lymphoma induced by imatinib, as a tyrosine kinase inhibitor, is a rare complication.<\/jats:p>\n <\/jats:sec>\n \n Case report<\/jats:title>\n A 54-year-old female with a history of chronic myeloid leukemia (CML) was treated with imatinib as first-line therapy. The patient achieved a profound molecular response with treatment-free remission after five years but lost major molecular responses. A second deep molecular remission was again achieved. Nine years after imatinib therapy, the patient developed odynophagia and rhinorrhea. Physical examination revealed enlarged tonsils with a tumor-like appearance without palpable lymph nodes. Immunohistochemical examination of the tonsils revealed a large B-cell lymphoma. According to Naranjo's algorithm, the causality relationship with the drug is possible with a score of 3.<\/jats:p>\n <\/jats:sec>\n \n Management and outcome<\/jats:title>\n Imatinib was discontinued. The lymphoma was treated with rituximab and chemotherapy.<\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n Non-Hodgkin's lymphoma is a rare side effect of tyrosine kinase inhibitors and highlights the importance of follow-up CML patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10781552221137700","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T20:54:57Z","timestamp":1667854497000},"page":"996-998","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Non-Hodgkin's lymphoma developed during imatinib mesylate treatment of chronic myeloid leukemia"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7081-3494","authenticated-orcid":false,"given":"Olfa","family":"Kassar","sequence":"first","affiliation":[{"name":"Department of Hematology University Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aicha Ben","family":"Kahla","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Koubaa","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-8565","authenticated-orcid":false,"given":"Faten","family":"Kallel","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imen Ben","family":"Amor","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moez","family":"Elloumi","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"bibr1-10781552221137700","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"bibr2-10781552221137700","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3770"},{"key":"bibr3-10781552221137700","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02620-2"},{"key":"bibr4-10781552221137700","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S5775"},{"key":"bibr5-10781552221137700","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2015.003"},{"key":"bibr6-10781552221137700","doi-asserted-by":"publisher","DOI":"10.1080\/14653240802317639"},{"key":"bibr7-10781552221137700","doi-asserted-by":"publisher","DOI":"10.1038\/387450a0"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221137700","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221137700","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221137700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:37Z","timestamp":1777688857000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221137700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1177\/10781552221137700"],"URL":"https:\/\/doi.org\/10.1177\/10781552221137700","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]}}}